DURECT Corporation to Announce Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 7

Rhea-AI Summary

DURECT Corporation (NASDAQ: DRRX) has announced it will report its fourth quarter and full year 2022 financial results on March 7, 2023, after market closure. The company is set to host a conference call at 4:30 PM ET to discuss the results. DURECT is known for its advancements in treatment for acute organ injury and chronic liver diseases, particularly its lead drug candidate Larsucosterol (DUR-928), currently in clinical development for alcohol-associated hepatitis with FDA Fast Track Designation. The company also holds an FDA-approved product, POSIMIR, licensed to Innocoll Pharmaceuticals.

Positive

• DURECT has FDA Fast Track Designation for Larsucosterol (DUR-928) targeting alcohol-associated hepatitis.
• The upcoming financial results announcement may provide insights into business performance and future guidance.

Negative

• Potential risks regarding the commercialization of POSIMIR by Innocoll.
• Concerns over the timeline of clinical trials for Larsucosterol due to external factors like COVID-19.

CUPERTINO, Calif., Feb. 28, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it will report its fourth quarter and full year 2022 financial results and host a conference call after the market close on Tuesday, March 7, 2023.

 

Tuesday, March 7 @ 4:30pm Eastern Time / 1:30pm Pacific Time
Toll Free:	1-877-869-3847
International:	201-689-8261
Conference ID:	13736560
Webcast:	https://event.choruscall.com/mediaframe/webcast.html?webcastid=Do9m0bih

 

About DURECT Corporation
DURECT is a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic regulator program. Larsucosterol (also known as DUR-928), DURECT's lead drug candidate, binds to and inhibits the activity of DNA methyltransferases (DNMTs), epigenetic enzymes which are elevated and associated with hypermethylation found in alcohol-associated hepatitis (AH) patients. Larsucosterol is in clinical development for the potential treatment of AH, for which FDA has granted a Fast Track Designation; non-alcoholic steatohepatitis (NASH) is also being explored. In addition, POSIMIR® (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the innovative SABER® platform technology, is FDA-approved and has been exclusively licensed to Innocoll Pharmaceuticals for development and commercialization in the United States. For more information about DURECT, please visit www.durect.com and follow us on Twitter https://twitter.com/DURECTCorp.

DURECT Forward-Looking Statements
This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, relating to: the development and commercialization of POSIMIR by Innocoll, the potential to develop larsucosterol for AH, NASH or other indications, and the potential benefits, if any, of DURECT's product candidates. Actual results may differ materially from those contained in the forward-looking statements contained in this press release, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties that could cause actual results to differ from those projected include, among other things, the risk that Innocoll may not commercialize POSIMIR successfully, the risk that the AHFIRM trial takes longer to conduct than anticipated due to COVID-19 or other factors, the risk that ongoing and future clinical trials of larsucosterol do not confirm the results from earlier clinical or pre-clinical trials, or do not demonstrate the safety or efficacy of larsucosterol in a statistically significant manner, and risks related to the sufficiency of DURECT's cash resources, DURECT's anticipated capital requirements and capital expenditures, DURECT's need or desire for additional financing, DURECT's ability to obtain capital to fund its operations and expenses and DURECT's ability to continue to operate as a going concern. Further information regarding these and other risks is included in DURECT's most recent Securities and Exchange Commission (SEC) filings, including its annual report on Form 10-K for the year ended December 31, 2021 and quarterly report on Form 10-Q for the quarter ended September 30, 2022 under the heading "Risk Factors."  These reports are available on DURECT's website at www.durect.com under the "Investors" tab and on the SEC's website at www.sec.gov. All information provided in this press release and in the attachments is based on information available to DURECT as of the date hereof, and DURECT assumes no obligation to update this information as a result of future events or developments, except as required by law.

NOTE: POSIMIR® is a trademark of Innocoll Pharmaceuticals Limited in the U.S. and a trademark of DURECT Corporation outside of the U.S. SABER® is a trademark of DURECT Corporation. Other referenced trademarks belong to their respective owners. Larsucosterol (DUR-928) is an investigational drug candidate under development and has not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities for any indication.

View original content:https://www.prnewswire.com/news-releases/durect-corporation-to-announce-fourth-quarter-and-full-year-2022-financial-results-and-provide-business-update-on-march-7-301758809.html

SOURCE DURECT Corporation

FAQ

When will DURECT Corporation announce its fourth quarter and full year 2022 financial results?

DURECT Corporation will announce its financial results on March 7, 2023.

What is the conference call schedule for DURECT's financial results?

The conference call is scheduled for March 7, 2023, at 4:30 PM ET.

What is Larsucosterol and what is its significance for DURECT Corporation?

Larsucosterol (DUR-928) is DURECT's lead drug candidate targeting alcohol-associated hepatitis and has received FDA Fast Track Designation.

What are the potential risks mentioned in DURECT's press release?

Risks include the successful commercialization of POSIMIR by Innocoll and delays in clinical trials for Larsucosterol.